Canine Mammary Tumor Treatment Market

Mammary Tumor is a tumor of the mammary tissue and is most common in unspayed dogs, and in dogs spayed after their first heat cycle. Dogs have five pairs of mammary glands with glands near the armpit region and in the glands located in inguinal area. The mammary tumor is frequently found in toy, miniature, spaniels, and German shepherd breeds. Male dogs are rarely impacted by this kind of tumor. Mammary tumors are found in various sizes and shapes, and can move to underlying tissue. Many dogs develop single tumor in one gland and others develop multiple tumors within same gland.

Canine Mammary Tumor Treatment Market contains market size and forecasts of Canine Mammary Tumor Treatment in Global, including the following market information:

• Global Canine Mammary Tumor Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Canine Mammary Tumor Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

By Type Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Canine Mammary Tumor Treatment include Oasmia Pharmaceuticals AB, Aratana Therapeutics, Inc., VetDC, Inc., AB Science, Boehringer Ingelheim International GmbH, Zoetis, VCA Hospitals, Karyopharm Therapeutics, Inc. and Rhizen Pharmaceuticals SA. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Canine Mammary Tumor Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Canine Mammary Tumor Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Canine Mammary Tumor Treatment Market Segment Percentages, by Type, 2021 (%)

By Type

• Adenomas
• Carcinomas
• Adenocarcinomas

By Treatment

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Chemotherapy
• Radiation Therapy
• Surgery
• Prognosis

Global Canine Mammary Tumor Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Canine Mammary Tumor Treatment Market Segment Percentages, by Application, 2021 (%)

• Veterinary Hospitals
• Veterinary Clinics
• Others

Global Canine Mammary Tumor Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Canine Mammary Tumor Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Canine Mammary Tumor Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Canine Mammary Tumor Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Oasmia Pharmaceuticals AB
• Aratana Therapeutics, Inc.
• VetDC, Inc.
• AB Science
• Boehringer Ingelheim International GmbH
• Zoetis
• VCA Hospitals
• Karyopharm Therapeutics, Inc.
• Rhizen Pharmaceuticals SA